This study aims to examine the dual effects of cannabis consumption on both positive and negative symptoms of schizophrenia, across laboratory and real-world contexts. By integrating ecological momentary assessment (EMA) with cognitive tasks such as reality monitoring, the research seeks to clarify how cannabis use influences symptom severity and cognitive functioning in individuals with schizophrenia. Gaining insight into these relationships may contribute to the development of more effective management strategies and ultimately improve outcomes for patients living with schizophrenia.
Clinically stable and in the residual (non-acute) phase of illness,
No change in antipsychotic treatment for at least 1 month,
Outpatient, ambulatory care,
No uncontrolled positive symptoms (assessed using PANSS)
Psychiatric comorbidities: autism, bipolar disorder.
Current criteria for any other substance use disorder except for nicotine use disorder.
Any medical condition hindering the study and/or use of the smartphone application.
Patients with somatic, cognitive or other disorders preventing the use of the device (deafness, impaired vision, illiteracy….).
Parallel
Ecological Momentary Assessment (EMA) and Reality Monitoring tasks
Other interventionUse of Ecological Momentary Assessment (EMA) and a mobile Reality Monitoring task
Presence of a statistically significant association between cannabis consumption and the reduction of negative symptoms
Presence of a statistically significant association between cannabis consumption and the exacerbation of positive symptoms with EMA scale
Presence of a statistically significant association between cannabis consumption and the exacerbation of positive symptoms
Presence of a statistically significant association between cannabis consumption and the reduction of negative symptoms with EMA scale
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
